Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products

Lorbrena® (Lorlatinib) SNDA In Previously Untreated Alk-Positive Lung Cancer Accepted For Priority Review By FDA

Published: 12/28/2020 21:36 GMT
Pfizer Inc. (PFE) - Lorbrena® (lorlatinib) Snda in Previously Untreated Alk-positive Lung Cancer Accepted for Priority Review by U.S. FDA.
Pfizer Inc - Prescription Drug User Fee Act (pdufa) Goal Date for a Decision by FDA is in April 2021.
Pfizer Inc - Supplemental New Drug Application for Lorbrena Being Reviewed Under FDA Real-time Oncology Review (rtor) and Project Orbis Pilot Programs.
Pfizer Inc - FDA Also Will Conduct Review Under Project Orbis.